Brief: Scynexis Inc Scynexis Is Recalling Brexafemme(Reg) (Ibrexafungerp Tablets) From Market

Scynexis

25/09/2023 13:37

Sept 25 (Reuters) - GSK plc  GSK.L :
    * SCYNEXIS INC: SCYNEXIS IS RECALLING BREXAFEMME(REG)
(IBREXAFUNGERP TABLETS) FROM MARKET
    * SCYNEXIS - NOT KNOWN WHETHER ANY IBREXAFUNGERP HAS BEEN
CONTAMINATED WITH A BETA-LACTAM COMPOUND
    * SCYNEXIS - BECAME AWARE NON-ANTIBACTERIAL BETA-LACTAM DRUG
SUBSTANCE IS MANUFACTURED USING EQUIPMENT COMMON TO
MANUFACTURING PROCESS FOR IBREXAFUNGERP
    * SCYNEXIS INC: PLACING A TEMPORARY HOLD ON CLINICAL STUDIES
OF
IBREXAFUNGERP, INCLUDING PHASE 3 MARIO STUDY
    * SCYNEXIS INC: TEMPORARY HOLD UNTIL A MITIGATION STRATEGY
AND A
RESUPPLY PLAN ARE DETERMINED
    * SCYNEXIS INC - NOT RECEIVED REPORTS OF ADVERSE EVENTS
ESTABLISHED TO BE DUE TO POSSIBLE BETA-LACTAM CROSS
CONTAMINATION

Further company coverage:  GSK.L 

 ((Reuters.Briefs@thomsonreuters.com;))